UPDATE: Stifel Nicolaus Cuts PT to $37 on Theravance Ahead of March PADAC Meeting
Stifel Nicolaus maintained Theravance (NASDAQ: THRX) with a Buy rating and lowered the price target from $40.00 to $37.00.
Stifel Nicolaus commented, "We expect the release of BREO briefing docs (likely March 4th/5th) and subsequent PADAC meeting to likely generate a meaningful amount of volatility in the stock. However, we continue to like the risk/reward at current levels and remain Buy-rated with $37 target price."
Theravance closed at $21.60 on Tuesday.
Latest Ratings for THRX
|May 2015||Cowen & Company||Downgrades||Market Perform|
|Jul 2014||Bank of America||Downgrades||Buy||Neutral|
|Jun 2014||Stifel Nicolaus||Downgrades||Buy||Hold|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.